Degradation studies of pentoxifylline: Isolation and characterization of a novel gem-dihydroperoxide derivative as major oxidative degradation product

Journal of Pharmaceutical and Biomedical Analysis

Volumn 53, Issue 3, 2010, Pages 335-342

  Mone, Mahesh Kumar ^a,b   Chandrasekhar, K B ^b  

^a Advinus Therapeutics Private Limited Bangalore   (India)

^b JNTUA COLLEGE OF ENGINEERING   (India)

Author keywords

Gem Dihydroperoxide; Oxidative stress; Pentoxifylline; Stability indicating; Ultra high performance liquid chromatography

Indexed keywords

1 (5,5 BIS HYDROPEROXY HEXYL) 3,7 DIMETHYL 3,7 DIHYDRO PURINE 2,6 DIONE; HYDROPEROXIDE DERIVATIVE; PENTOXIFYLLINE; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; DRUG DEGRADATION; DRUG ISOLATION; DRUG STABILITY; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; OXIDATION-REDUCTION; OXIDATIVE STRESS; PENTOXIFYLLINE; PEROXIDES;

EID: 77954860138     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2010.04.006     Document Type: Article

References (22)

1. Ward A., Clissold S.P. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 1987, 34:50-97.
2. Porter J.M., Cutler B.S., Lee B.Y., Reich T., Reichle F.A., Scogin J.T., Strandness D.E. Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am. Heart J. 1982, 104:66-72.
3. Frampton J.E., Brogden R.N. Pentoxifylline (oxpentifylline). A review of its therapeutic efficacy in the management of peripheral vascular and cerebrovascular disorders. Drugs Aging 1995, 7:480-503.
4. Shen M.-R., Chiang P.-H., Yao R.-C., Hong C.-Y., Chen S.-S. Pentoxifylline stimulates human sperm motility both in vitro and after oral therapy. Br. J. Clin. Pharmacol. 1991, 31:711-714.
5. Indravadan Bhoir C., Bhanu Raman M., Sundaresan M., Bhagwat A. Separation and estimation of seven vasodilators using packed column supercritical fluid chromatography. J. Pharm. Biomed. Anal. 1998, 17:539-546.
6. Bauerová K., Soltés L., Kállay Z., Schmidtová K. Determination of pentoxifylline in serum by high-performance thin-layer chromatography. J. Pharm. Biomed. Anal. 1991, 9:247-250.
7. Szymura-Oleksiak J., Ślósarczyk A., Cios A., Mycek B., Paszkiewicz Z., Szklarczyk S., Stankiewicz D. The kinetics of pentoxifylline release in vivo from drug-loaded hydroxyapatite implants. Ceram. Int. 2001, 27:767-772.
8. Robert Smith V., Yang S.-K., Patrick Davis J., Michael Bauza T. Determination of pentoxifylline and its major metabolites in microbial extracts by thin-layer and high-performance liquid chromatography. J. Chromatogr. 1983, 23:281-287.
9. Ostrovská V., Pechová A., Kovácová D., Svobodová X., Kusala S. Determination of pentoxifylline and its major metabolites in human plasma using HPLC. Cesk. Farm. 1990, 39:158-160.
10. Wong J.W., Yuen K.H., Peh K.K. Simple high-performance liquid chromatographic method for determination of pentoxifylline in human plasma. J. Chromatogr. B: Biomed. Sci. Appl. 1998, 716:387-391.
11. Rieck W., Platt D. Determination of 3,7-dimethyl-1-(5-oxohexyl)-xanthine (pentoxifylline) and its 3,7-dimethyl-1-(5-hydroxyhexyl)-xanthine metabolite in the plasma of patients with multiple diseases using high-performance liquid chromatography. J. Chromatogr. 1984, 305:419-427.
12. Patrick K.B., Kim A.G., Kramer K.E., Robert B.C., Rodney Use of liquid chromatography-tandem mass spectrometry for the analysis of pentoxifylline and lisofylline in plasma. Biomed. Chromatogr. 2005, 19:231-236.
13. Elizabeth K.C., Fragrance C.C., Larry Y.M. Urinary excretion of pentoxifylline and its metabolites by standard bred mares. Can. J. Vet. Res. 1989, 53:147-153.
14. Mircia E., Imre S., Sipos E., Avrigeanu V., Popovici A., Hancu G. Study of pentoxifylline chemical stability from modified release tablets with hydrophilic mould. Proceedings of the 2008 First International Conference on Complexity and Intelligence of the Artificial and Natural Complex Systems. Medical Applications of the Complex Systems. Biomedical Computing 2008, 231-242.
15. Kuriki T., Matsubara K., Tsujiyama T., Sano A., Suzuki N. Physicochemical properties and stability of 1-(5-oxohexyl)theobromine (pentoxifylline). Iyakuhin Kenkyu 1977, 8:202-211.
16. Tsujiyama T., Ohsaki T., Matsubara K., Sano A., Kuriki T., Suzuki N. Studies on xanthine derivatives: formation of tricyclic heterocycles from hydrolysates of 1-(5-oxohexyl) theobromine. Chem. Pharm. Bull. 1982, 30:3088-3091.
17. Monika B., Tina O., Singh S. Validated specific HPLC methods for determination of prazosin, terazosin and doxazosin in the presence of degradation products formed under ICH-recommended stress conditions. J. Pharm. Biomed. Anal. 2004, 34:19-26.
18. ICH Stability Testing of New Drug Substances and Products (Q1AR). International Conference on Harmonization, IFPMA 2000.
19. Alsante K.M., Ando A., Brown R., Ensing T., Hatajik D., Kong W., Tsuda Y. The role of degradant profiling in active pharmaceutical ingredients and drug products. Adv. Drug Deliv. Rev. 2007, 59:29-37.
20. Bartick E.G., Merrill R.A., Mount K.H. Analysis of a suspect explosive component: hydrogen peroxide in hair coloring developer. Forensic Sci. Commun. 2001, 3.
21. Zmitek K., Zupan M., Stavber S., Iskra J. Iodine as a catalyst for efficient conversion of ketones to gem-dihydroperoxides by aqueous hydrogen peroxide. Org. Lett. 2006, 8:2491-2494.
22. Hamada Y., Tokuhara H., Masuyama A., Nojima M., Kim H.-S., Ono K., Ogura N., Wataya Y. Synthesis and notable antimalarial activity of acyclic peroxides, 1-(alkyldioxy)-1-(methyldioxy)cyclododecanes. J. Med. Chem. 2002, 45:1374-1378.